BIOMIT Center for Molecular Immunology - CIM





The Federation of Cuban Women (FMC) granted, for the only time, the Seal 60 Aniv. from the Federation of Cuban Women at the proposal of the National Secretariat to a group of 17 CIM scientists linked to Sovereign vaccine.


The Ministry of Science, Technology and Environment awards the Award for Technological Innovation to several projects that have stood out for their contribution to national development and for their impact on society, among which is our monoclonal antibody Itolizumab, for its repositioning in the treatment of patients with COVID-19 and its evident therapeutic action in severe psoriasis, an incurable autoimmune disease of the skin.
In the same way, by Presidential Decree 182 the Carlos J. Finlay Order is granted to 23 outstanding specialists in investigative activity with scientific value and impact on science, the economy, society and the environment, among which two stand out. outstanding scientists of our Center; Dra. Tania Crombet and DraC. Belinda Sanchez.


BioCubaFarma's Strategy for the Productive Development of vaccine candidates is divided into three dimensions:
Technological scientist
The CIM is inserted in the 3 dimensions, from the articulation with the Finlay Institute of Vaccines and the Center for Genetic Engineering and Biotechnology, in research and development, the contribution of the RBD protein for the 4 vaccine candidates, the evaluation of the samples of patients from the Soberana01 / 02 clinical trials, to the manufacturing of the batches for the clinical trials and the production scaling of Soberana 01 and 02.


The CIM PCR laboratory has been working intensively for more than 6 months in the processing of samples to detect COVID-19. This has been possible to the team made up of workers from different areas of the Center, research, quality and production, and to a 24-hour shift work from Monday to Monday. 400 daily samples have been processed stably, but at the beginning of the year the epidemiological situation in the country intensified, 10 new workers from the purification and fermentation area have been added to reinforce the work. This work has not only been an opportunity to support the confrontation of the pandemic, but also a new learning of techniques and modes of organization, which has motivated everyone, with the youngest standing out in their disposition and commitment.


The application of the monoclonal antibody itolizumab in critical, severe and moderate COVID-19 patients shows radiological improvement in the lungs of these patients at
only 24 hours after being treated with a dose of itolizumab, obtaining a survival of 90%, which supports its effectiveness in this condition, being included in the approved version of the protocol.


Yesterday afternoon, the signing of a scientific collaboration agreement between the Finlay Vaccine Institute of Cuba and the Pasteur Institute of Iran took place, which will aim to promote the joint development of vaccines against COVID-19, having today as a point starting from the completion of clinical evidence, the ongoing project of the Sovereign02 vaccine, carried out between the Finlay Institute and our Center.


The year 2020 was full of complexities, sacrifice and uncertainty, but the CIM closed with a balance of great moments and results, which brought us new learning in new ways of working, reinforced our organizational values, uniting us even more for a common purpose, It encouraged creativity, promoted consecration, today we feel satisfied and motivated to continue in the same way, providing hope and health to the people


When COVID 19 invaded Cuba, and the world was facing this pandemic, there were the youth and workers of the CIM transforming it into new opportunities:
• We developed a protocol for the Use of Itolizumab mAb in severely COVID patients, and many lives have been saved thanks to this product.
• We developed a protocol for the Use of EPO and G-CSF in severe COVID patients.
• Together with our brothers from IFV, we developed two vaccine antigens for the SOBERANA 01 and 02 vaccines that are currently being evaluated at the Clinic.
• We developed three R-Fc molecules for the ICD diagnostic kits in the determination of IgG and IgM.
• We develop recombinant molecules to evaluate the immune response of vaccine candidates.
• We set up a PCR Laboratory with 40 workers, almost all of them young, who work 12 hours a day, process 440 samples a day and have accumulated more than 33,000 samples.

For this same reason, the CIM received in the act for the 26th anniversary, the Labor Prowess Banner of the SNTC and the Seal of Humanism, Sensitivity and Solidarity.
More than that, the 80th Anniversary Seal of the CTC Foundation was awarded to Dr. Tania Crombet, Director of Clinical Research of the Center, the "Young People for Life" Plaque to the CIM, the Youth for Life Distinction to 96 young people.
At the same time, it was opportune to recognize Dr. Agustin Lage by the CIM collective, for having received the title of Dr. Honoris Causa in Biological Sciences.


There are many people and organizations wanting to be part and contribute to everything that science and health are doing to combat the pandemic in Cuba.

This time the protagonist is called Abel, who works in the CreareUP Group and they have donated 100 pullovers for the SOBERANA01 project, 50 for the Finlay Institute and 50 for the CI

Gesture such as that of this Group that join the many who want to contribute, are contributing and will continue to do so.

Applause for you too.


The CIM joins the group of PCR diagnostic laboratories for COVID19 and in less than 15 days it trained its staff and assumed new techniques to immediately contribute to the processing of more samples in the country. A young team of researchers are working 24x24 today and have managed to exceed the daily figures of 200 samples with great effort and commitment to science and the health of the Cuban people.

Mostrando 10 de 59 registros
Phone Board:
General Direction:
15 Street and 216 Street, Siboney, Playa, La Habana, Cuba. A.P 16040, La Habana 11600, Cuba
Postal Code:
11 600
Post Office Box:
16 040

Frequent Questions

How can I access the therapeutic vaccines against lung cancer?

Cuba has 2 therapeutic vaccines for advanced lung cancer:
CIMAvax EGF ® and VAXIRA ® (racotumomab). Both therapeutic vaccines have sanitary registration in the indication of stage III and IV advanced non-small cell lung cancer (NSCLC), after the first line of chemotherapy. The main clinical benefit of these vaccines has been shown to be increased survival and improved quality of life, as well as a broad safety profile.

How to acquire the vaccines?
Foreigners should contact the Cuban Medical Services who will evaluate each case as part of a comprehensive patient care program, with commercial value.

-Cuban Medical Services. Web page:; E-mail:
Phone: (537) 209-0977 Fax: (537) 203-1590.

You can also make your request for care expressing the reason for your request, a medical summary and personal data directly to:

International Clinic of the Hermanos Ameijeiras Hospital.
Calle San Lázaro # 701 esq. to Belascoaín, Havana Center, Havana, C.P: 10400, Cuba.
Telephone: (537) 8761029, (537) 8761030, (537) 8761683. Email:

International Health Center
La Pradera Calle 15 between 222 A and 234, Siboney neighborhood, Playa Municipality, Havana, Cuba
Telephone: (+537) 273 7467 Ext. 403 (+537) 2737202. Email:

Mas preguntas frecuentes...


We ensure the quality, safety and effectiveness of our medicines.
We offer information on the use of our products to patients, families and professionals.
Your contribution is very important..
Report suspected adverse reactions here: